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Abstract
Fibrosis is a part of the wound-healing response to tissue damage and characterized by
excessive  accumulation of  mainly  type  I  collagen-containing extracellular  matrices
(ECMs). Transforming growth factor beta (TGF-β) is a profibrogenic master cytokine
responsible for promoting differentiation of tissue-resident fibroblasts into myofibro‐
blasts, upregulation of ECM production, and downregulation of ECM degradation. The
formation of ECM is an essential response in wound healing. Fibronectin is an ECM
glycoprotein substantially expressed during tissue repair. Based on in vitro findings, it
has been widely accepted that collagen network organization was exclusively fibronec‐
tin matrix dependent. Unexpectedly, our fibronectin conditional knockout mouse models
have demonstrated a fibronectin-independent mechanism of collagen fibril formation
following injury and identified TGF-β signaling and type V collagen as essential elements
for collagen fibrillogenesis. Interestingly, the targeting of the TGF-β signaling alone, as
proposed in some recent antifibrotic therapies of chronic fibrotic diseases, is not sufficient
to completely prevent liver fibrosis. In this chapter, we focus on the present knowledge
of the mechanisms of the collagen network organization following tissue/organ damage
and pathological processes of chronic fibrotic diseases.
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1. Introduction
Cells in virtually all tissues are in contact with organized complexes of structural molecules
collectively called the extracellular matrix (ECM). ECM induces a variety of signals that
regulate the behavior of cells, such as differentiation, adhesion, and migration, and also
fundamental physiological processes such as embryonic development and tissue regeneration
and remodeling [1]. As a consequence, tissues or organs keep their normal architecture and
homeostasis. Aberrations in signal transduction from the ECM cause chronic degenerative and
fibrotic disorders.
Considering the adult tissue/organ remodeling following injury, an important unresolved
question is how newly deposited ECM contributes to the critical turning point from normal to
abnormal healing. Wound healing is a crucial response to maintain tissue/organ structure and
integrity after tissue damage, and also tissue/organ homeostasis [2]. Fibrosis is a part of the
wound-healing response that maintains organ structure and integrity following tissue
damage. However, excessive fibrosis contributes to a number of diseases. Indeed, fibrosis is
the common pathological end result of many chronic inflammatory diseases. Fibrosis is an
abnormal extension of the wound-healing process that follows tissue damage, characterized
by the excessive accumulation of collagenous ECMs. The hallmark of fibrosis is excessive
accumulation of mainly type I collagen (Col I) containing ECMs, and therefore involves both
wound-healing and fibrotic processes. Fibrosis is recognized as a major cause of morbidity and
mortality in most chronic diseases and chronic graft rejection, and also influences tumor
invasion and metastasis. Importantly, a critical event in all fibrotic diseases is the activation of
myofibroblast, which are the key mediators of fibrotic tissue remodeling [3].
The clarification of regulatory mechanisms underlying excessive accumulation of ECMs in
parenchymal organs such as livers during the development of chronic fibrotic diseases is a
critical issue. However, currently, the main barrier to designing novel antifibrotic strategies is
due to our insufficient understanding of the mechanisms responsible for ECM-network
formations following tissue/organ injury. This gap in knowledge translates to lack of experi‐
mental models of repair in vivo, including gaps in the understanding of the identity and
molecular control of factors and cells participating in the repair processes following injury. In
this chapter, we will focus on the present knowledge of the mechanisms of the collagen-
network organization following tissue/organ damage and pathological processes of chronic
fibrotic diseases.
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2. Molecules critical for collagen network formation
2.1. Fibronectin
Fibronectin, a dimeric glycoprotein, exists in two isoforms: a soluble isoform in plasma
(plasma-type fibronectin, produced solely by hepatocytes) and an insoluble isoform in tissue
ECM (cellular-type fibronectin, produced by a variety of cells). Both isoforms are generated
from a single gene by alternative splicing [4]. Although considerable in vitro functional studies
have indicated that fibronectin isoforms play key roles in cell differentiation, proliferation,
migration, and survival [5, 6], knowledge of the functional identity of each fibronectin isoform
in adult tissue remodeling remains loosely defined due to the complexity and the lack of the
systems. Indeed, a prominent expression of fibronectin is often observed during adult tissue
repair [7]. In response to adult tissue damage, the initial “provisional matrix” formation
between plasma-type fibronectin and fibrinogen stabilizes wounded area, which acts as a
nidus for subsequent collagen fibrillogenesis [7, 8]. Little insight into the pathophysiological
roles of fibronectin has emerged from studies of genetic changes in humans. There are no
documented cases of fibronectin-null patients, the nearest condition being familial glomeru‐
lonephritis in which there are mutations in the type III modules of fibronectin [9]. While
complete fibronectin-null mice show an embryonic lethal phenotype [10], experimental
evidence has documented that skin wounds heal normally in mice lacking plasma-type
fibronectin [11]; hence, an absolute requirement for fibronectin in response to adult tissue
damage has been speculative.
Based on in vitro findings, it has been postulated that collagen network formation depends on
the fibronectin matrix [12, 13]. It was, therefore, hypothesized that the removal of fibronectin
from the in vivo system could abolish extensive ECM network formation following tissue
damage. To define the functional identity of fibronectin in adult tissue remodeling, we recently
established a null condition for both fibronectin isoforms in adult liver (fibronectin(fl/fl)/Mx-
Cre+). We have demonstrated an unexpected finding that the lack of fibronectin does not
interfere with reconstruction and resolution of collagen fibril organization after the initial
stages of liver injury. We have discovered a fibronectin-independent mechanism of collagen
fibrillogenesis and identified transforming growth factor beta (TGF-β) signaling and type V
collagen (Col V) as essential elements for collagen fibrillogenesis in response to liver injury [14]
(further discussed in Section 3).
2.2. Transforming growth factor-β (TGF-β)
Transforming growth factor (TGF)-β is a profibrogenic master cytokine responsible for
promoting differentiation of tissue-resident fibroblasts into myofibroblasts, upregulation of
ECM production including fibronectin, and downregulation of ECM degradation [15–18].
TGF-β is secreted as a biologically inactive (latent) form, and importantly, the active TGF-β
levels do not often correlate with mRNA and protein levels [19]. Indeed, the activation of latent
TGF-β occurs independently of transcription [20], and the bioassay to measure active TGF-β
levels has been developed using a mink lung cell line (TMLC) stably transfected with a
plasminogen activator inhibitor-1 (PAI-1) promoter fused to luciferase [21].
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TGF-β is secreted in a biologically inactive (latent) form in a complex (large latent complex
[LLC]) with TGF-β latency associated protein (LAP) [22] and latent TGF-β binding proteins
(LTBPs) [23]. Prior to the secretion, TGF-β is synthesized as a precursor and forms dimerized
complex through disulfide bonds intracellularly. The dimer precursor is proteolytically
cleaved by endopeptidase furin to generate LAP and mature TGF-β peptide from the N-
terminal and C-terminal portions, respectively [24, 25]. Interestingly, LAP still associates with
mature TGF-β noncovalently, termed as small latent complex. In vitro studies demonstrate that
LAP is required for the secretion of TGF-β from cells [26, 27]. Furthermore, LAP shields the
receptor binding epitope of mature TGF-β, indicating that LAP plays an inhibitory role in
binding to its receptors [18]. Small latent complex is further associated with a secreted large
glycoprotein LTBP via disulfide bonds. These trimolecular complexes (TGF-β, LAP, and LTBP)
termed as LLC are formed intracellularly, then secreted and incorporated into ECM. An in
vitro observation reveals that LLC and free LTBPs are secreted rapidly from cells as early as
30 min after synthesis, whereas small latent complex is secreted slowly [28]. Another study
using TGF-β expressing CHO cells shows that only 50% of recombinant TGF-β precursor is
secreted at 6 h after radio labeling with [35S] cysteine and [35S] methionine, and the level of its
secretion becomes plateau at 20 h [29]. Secreted LLCs deposit in ECM via LTBPs. LTBPs are
extracellular multidomain glycoproteins and share homology with fibrillins, which are the
major constituents of connective tissue microfibrillar structure [25, 30–32]. Four different
isoforms (LBTP 1-4) have been identified, and each isoform includes four 8-cystein domains
and numerous epidermal growth factor (EGF)-like motifs [32]. Three isoforms, LTBP-1, 3, and
4, are known to associate with LAP via the third 8-cystein domain, whereas LTBP-2 does not
bind to latent TGF-β [32]. In addition, LTBPs interact with extracellular proteins such as
fibrillin-1, fibronectin, heparin, and myostatin [32–36]. Indeed, LTBP-1 colocalizes with both
fibrillin-1 and fibronectin in vitro [33, 36]. Thus, LTBP-1 plays a central role in secreting and
anchoring latent TGF-β into ECM (see Section 3).
In response to injury, the conformation of LLC changes and/or TGF-β is released from LAP,
resulting that active TGF-β is exposed to its receptor binding site [37]. Indeed, elevated TGF-
β bioavailability is frequently observed in chronic fibrotic diseases, and the inhibition of local
TGF-β activation can protect against the progression of fibrosis in several adult chronic fibrotic
diseases [38–41]. There are several mechanisms of local TGF-β activation, which mediates αvβ6
and αvβ8 integrins, and thrombospondin-1 (TSP-1). Integrin αvβ6 can directly activate latent
TGF-β, which depends on an interaction with RGD amino acid sequence of LAP [25]. In
response to injury, integrin αvβ6 induces a conformational change (deformation) of LAP via
the interaction between αvβ6 and the cytoskeleton [25, 42, 43]. Consequently, such a defor‐
mation makes it possible to release active TGF-β from LAP and then cause mature TGF-β to
interact with TGF-β type II receptor (TRII) [25, 42, 43]. Interestingly, this activation process is
independent of any proteolysis [25]. In contrast, integrin αvβ8-mediated activation of TGF-β
is shown to be dependent on membrane type 1-matrix metalloprotease (MT1-MMP, also
known as MMP-14) [44]. Furthermore, this activation does not require β8-cytoplasmic domain
[44]. These findings indicate that the mechanism of αvβ8-mediated TGF-β activation is clearly
different from that of αvβ6. In vitro and in vivo studies demonstrate that TSP-1 can also activate
latent TGF-β [45, 46]. TSP-1 is a matricellular protein prominently expressed in response to
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tissue damage and plays a role as a transient component of ECM during tissue repair [47].
TSP-1 directly interacts with the LAP [48], and the interaction is supposed to induce a confor‐
mational change of LAP, thereby presumably uncover TGF-β receptor binding site [49, 50]. In
addition, MMP-2, 9, 13, bone morphogenetic protein (BMP)-1, and serine proteases (plasmin,
thrombin, neutrophil elastase, and kallikrein) have been shown to play an important role in
TGF-β activation at least in vitro [51, 52]. A very recent study reveals plasma kallikrein-
dependent TGF-β activation in fibrotic liver in both animal models and patients [53].
Smads are the central as direct downstream modulators in canonical TGF-β signaling [54–56].
Smads consist of three classes: regulatory/receptor-activated (Smad2 and Smad3), coactivating
(Smad4), and inhibitory Smads (Smad6 and Smad7). TGF-β binding to TRII initiates the
formation of the complex with the TGF-β type I receptor (TRI) and phosphorylation of TRI.
Subsequently, they activate TRI phosphorylates of Smad2 and Smad3, and then they form
complexes with Smad4. These complexes bind to specific motifs “Smad-binding element” with
transcription factors/coactivator such as Ap-1, Sp1, and CBP/p300, and promote the gene
expression [54, 57]. Lines of evidence suggest that TGF-β signaling plays a key role in regu‐
lating myofibroblast phenotypes and fibrosis in the heart, lungs, liver, kidneys, and skin [3,
54]. For example, TGF-β directly induces the transdifferentiation of fibroblasts into collagen-
secreting active myofibroblasts [3, 14, 58], and overexpression of TGF-β results in the induction
of hepatocyte apoptosis and liver fibrosis [18, 59, 60]. In contrast, TGF-β1 knockout mice show
remarkable (~80%) decrease of collagen accumulation in response to liver injury [58, 61].
Furthermore, Smad3-null mice show reduction in liver fibrosis with decreased myofibroblast
activation and ECM production in response to liver injury, whereas the disruption of inhibitory
Smad7 results in an enhancement of damage and fibrogenesis in chronic liver injury [7]. We
have previously generated adult mice lacking TRII from livers (TGF-βIIR(fl/fl)/Mx-Cre+);
because TRII is the exclusive type II receptor for all TGF-β ligands, lack of this receptor
abolishes all TGF-mediated signaling in the liver. Knockout livers actually show significantly
lower ECM deposition (~46% compared to controls) in carbon tetrachloride (CCl4)-induced
chronic injury, which is accompanied by the decreased expression of myofibroblast marker
alpha-smooth muscle actin (α-SMA). These findings indicate that TGF-β signaling is indeed a
dominant pathway in the development of liver fibrosis [62]. However, elimination of TGF-β
or TRII does not completely prevent the accumulation of Col I in chronic liver injury, and in
particular, TRII knockout livers still remain ~46.4% fibrosis compared to wild type [61, 62].
Therefore, these findings clearly indicate the TGF-β-independent mechanism(s) in the
development of liver fibrosis (see Section 3). Indeed, we have found that TRII-null livers
significantly upregulated connective tissue growth factors (CTGF/CCN2) following chronic
liver injury, suggesting that CTGF/CCN2 can be an alternative mediator in liver fibrosis.
As described above, the local activation of latent TGF-β is a critical step in TGF-β-mediated
fibrosis [37, 42, 63, 64]. We have discovered that fibronectin-null livers show elevated local
TGF-β bioavailability and upregulate Smad signaling in activated hepatic stellate cells (HSCs)
following injury [14, 65]. This novel finding implies that fibronectin regulates the balance
between active and inactive (latent) TGF-β, which in turn modulates ECM production and
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remodeling following injury, and consequently retains adult tissue/organ functions. We
further describe this important topic in the following section.
2.3. Type I/type V collagen
Collagens are the most abundant scaffolding ECM in tissue/organ stroma and contribute
significantly to tissue/organ integrity [66, 67]. The collagen superfamily is large and hetero‐
geneous, and there are at least 28 different collagen types in vertebrates [66, 68]. A collagen
molecule consists of three polypeptide chains called α chains, displays a right-handed
supercoil, and also has one or more triple helical regions with common sequence repeats, Gly-
X-Y [69]. Collagens are divided into six subfamilies (or subgroups) based on their structure,
function, and distribution [66, 67]. The collagens that we focus in this review are Col I and Col
V and those belong to fibril-forming collagens. Fibril-forming collagens are synthesized as
procollagen and three pro α chains fold a triple helical structure from its C-terminus to N-
terminus [67]. To form ordered fibrils, both N- and C-propeptides should be cleaved by
procollagen N-proteinases/ADAMTS-2, 3, 14, and procollagen C-proteinases/BMP-1/tolloid
proteinases, respectively [68]. An exception to this is the case in Col α1(V) chain. Its C-
procollagen is cleaved by furin, and its N-terminal is cleaved by BMP-1 [70]. The peptides
cleaved by proteinase are called “propeptides” and noncollagenous peptides remain after the
enzyme cleavages called “telopeptides”. The telopeptides of Col I contain intermolecular
crosslinking sites for fibrillogenesis [71]. Fibril-forming collagens form the 64–67 nm regularly
repeated striated fibrils [72]. When collagen I molecules form fibrils, there is a unique space in
the collagen fibrils termed “gap zone”. The gap zone is present between the N-terminus of one
molecule and C-terminus of the next in the triple helix-formed collagen fibrils, and the gap
zone is suggested to play a role in a variety of molecular interactions, including lysyl oxidase
(LOX)-mediated collagen cross-linking [73, 74].
Collagens are essential for tissue-specific macromolecular structure and organizations in the
ECM. Indeed, collagen-mediated ECM networks affect many important biological properties
such as matrix/tissue stiffness and tissue/organ structure. Collagens participate in numerous
physiological processes such as embryonic development, and tissue regeneration and remod‐
eling [75]. Collagen networks provide the biomechanical scaffold for cell attachment and trap
of macromolecules, and regulate cell growth and proliferation, and also the shape and
structural integrities of cells and tissues [1, 76]. While collagens exist outside of cell and are
composed of ECM structures, cells always sense the alterations of their ECMs, produce new
ECMs, and/or degrade their ECMs, and consequently, tissues/organs maintain their homeo‐
stasis. More importantly, collagens induce intracellular signaling pathways, and it is mediated
by cell surface ECM receptor, integrins. Integrins are transmembrane αβ heterodimeric
receptors that mediate organization of focal contacts, actin-containing cytoskeleton, and ECM.
Integrins are a major family of cell-surface-adhesion receptors (composed of 18 α-subunits and
8 β-subunits) [77]. The ligation of integrins by adhesive ligands can induce intracellular
signaling events (“outside-in” signaling) and intracellular signaling pathways can control
binding avidity of integrins for extracellular ligands (“inside-out” signaling) [77]. Interesting‐
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ly, there is a “cross-talk” between integrins and receptor tyrosine kinases in certain cell types
[78–80].
Several unique features of collagens are spotlighted as targets of medical treatment or
biomarkers for diagnosis. For examples, oral administration of Col V induces immunologic
tolerance to lung allografts and downregulates lung allograft rejection [81]. Another study
shows using a specific monoclonal antibody against Col V C-terminal propeptide that, in the
liver fibrosis patients, Col V C-terminal propeptide levels released in the serum have a positive
correlation with the total amount of collagens deposited in the fibrotic livers. This finding has
a potential to be used as diagnostic and potentially prognostic markers in monitoring liver
fibrosis [82].
Considering the mechanisms in collagen fibril network organization, two key molecules, Col
V and Col XI, are involved in this process. Although both collagens are fibrillar collagens and
minor components in tissues/organs, they play an important role in controlling fibril diameter
of assembled collagen [83]. Col V [two α1(V) and one α2(V)] is known to form heterotypic
fibrils with Col l [76]. Col V has a conserved multidomain structure, N-terminal domain [73].
Col V controls collagen fibril diameter through both triple helical [84] and N-terminal domains
[83, 85]. There is evidence that Col V regulates the fibril diameter in vitro [73, 84, 86]: Col I alone
formed a broad distribution of relatively large diameter fibrils, while Col V alone formed much
thinner nonperiodic fibrils. Interestingly, fibrils formed from Col I in the presence of increasing
amounts of Col V displayed a significant decrease in the mean fibril diameter. The variance of
the fibril population is also decreased as the percentage of Col V increases. Despite of presence
of Col I, deletion of col 5a1 gene causes embryonic lethal in a mouse model due to a virtual lack
of fibril formation in the mesenchyme [87]. The heterozygous mice (col 5a1 [+/–]) are viable,
but show the reduction of fibril number and collagen content in the skin compared to wild-
type mice. Furthermore, the abnormal collagen fibrils are observed in the deep dermis of col
5a1 (+/–) mice; the mutant fibrils display larger diameter and broad distribution, and the
diameter is inconsistent along the fibril length. These findings show that col V is essential for
Col I fibril assembly.
Col XI [α1(XI), α2(XI), α3(XI)] is known to form heterotypic fibrils with Col II. Col XI α-chains
shares structural homology with Col V and appears to have a similar nucleating function [88].
The first half of the human α1(V) N-propeptide has 73% homology with the human α1(XI)
chain [83]. The α1 (XI) chain loses its function by chondrodysplasia mutation [89]. Loss of
function mutations in the α1 (XI) chain leads to the assembly of Col II and Col V fibrils with
abnormally large diameters [73, 89]. This interesting observation clearly indicates that Col XI
also have a role to regulate the fibril diameter as Col V. To date, very little evidence in Col XI-
mediated fibrillogenesis has been identified, and more detailed studies in the functional role
of Col XI remain to be elucidated.
Recently, Burlingham et al. have shown an attractive evidence that Col V is involved in
immune response to adult human lung disease, obliterative bronchiolitis (OB), which is
characterized by narrowing of bronchiole lumens due to the inflammation and fibrosis [90].
Col V is recognized as an antigen by monocyte and presented to CD4+ T cells (called Th-17),
and Col V-specific responses are required both IL-17A produced by Th-17 and the monokines
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TNF-α and IL-1β, suggesting that IL-17A induced in response to Col V plays a role in fibrosis.
Indeed, IL-17A plays a variety of significant roles in neutrophil recruitment, angiogenesis,
inflammation, and autoimmune disease [91]. Very recently, Vittal et al. have shown a unique
observation about the relationship between Col V and IL-17A [92]. IL-17A can induce epithe‐
lial–mesenchymal transition in rat lung epithelial T-antigen negative cells through upregula‐
tion of S100A4 and mesenchymal marker α-SMA, and downregulation of epithelial markers
ZO-1 and E-cadherin. Mechanistically, IL-17A results in the downregulation of Smad7, and
upregulation of TGF-β and Smad3 activation, clearly indicating that IL-17A is involved in TGF-
β pathway. Col V is upregulated by TGF-β during osteogenesis [93], and we have demon‐
strated TGF-β-induced Col V-mediated de novo Col I and Col III network organization even in
the absence of fibronectin [14]. Thus, these findings suggest that IL-17A can act as an upstream
mediator to regulate the expression of Col V via TGF-β signaling-mediated pathway, and as
a consequence, IL-17A could modulate Col V-mediated fibrogenesis. There is another obser‐
vation showing that IL-17A is involved in liver fibrosis. Mouse primary HSCs are shown to
express IL-17A receptor (IL-17R). The treatment of HSC with recombinant IL-17A upregulates
α-SMA, collagens, and TGF-β mRNA expression levels. Furthermore, the IL-17RA-null mouse
model shows ~50% reduction of liver fibrosis induced by CCl4 with decreased levels liver
damage and inflammations [94], suggesting that IL-17A plays a significant role in HSC
transdifferentiation into active myofibroblasts during the development of liver fibrosis. Thus,
further analysis of the regulatory mechanisms of Col V by IL-17A could open the new avenue
as a drug target for liver fibrosis.
2.4. Other modifying molecules such as lysyl oxidase and small leucine-rich proteoglycans
Collagen contributes significantly to tissue/organ integrity, and collagen cross-linking stiffens
the ECM [1]. A recent elegant study has demonstrated that collagen cross-linking leads to
cancer progression by enhancing ECM receptor integrin signaling [95, 96]. However, the
functional contribution of collagen cross-linking to noncancer pathogenesis remains largely
unknown. The LOX family enzymes are copper-dependent amine oxidase and catalyze the
post-translational modification of peptidyl lysine to the peptidyl aldehyde, α-aminoadipic-δ-
semialdehyde [97]. This chemical change enables the covalent cross-linking of collagen and
elastin, resulting in insolubilizing and stabilizing ECM proteins. Collagen cross-linking stiffens
the ECM and is accompanied by tissue/organ fibrosis that is mediated by several profibrogenic
cytokines [95, 98]. Indeed, LOX inhibitor β-aminopropionitrile (BAPN) reduces organ stiffness
following injury and TGF-β1-induced collagen fibril stiffness in vitro [65, 99]. Lines of study
show that LOX localizes in ECM of several tissue such as skin, aorta, heart, lung, liver, and
cartilage [97]. LOX is secreted as inactive proenzyme (proLOX) and then proteolytically
cleaved to active enzyme. In vitro study shows the possibility that the activation of proLOX
occurs on the cell surface in a complex with cellular fibronectin. Indeed, LOX colocalizes well
with assembled fibronectin fibrils in cultured fibroblasts and normal human tissues [100].
Furthermore, fibronectin-null mouse embryonic fibroblasts exhibit drastic decrease of the
proteolytic processing of proLOX [100], strongly suggesting that fibronectin matrix regulates
ECM stiffness via LOX activation.
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Small leucine-rich proteoglycans/proteins (SLRPs) such as decorin, biglycan, and fibromodu‐
lin are known to contribute significantly to collagen assembly. SLRPs consist of five classes,
and almost all SLRPs bind collagen fibrils through their leucine-rich repeat domain [101–103].
Accumulating evidence using SLRP-null mouse models shows that SLRPs regulate the
diameter and/or alter structure of collagen fibrils [101–103]. For example, decorin knockout
mouse skin exhibits a broader range of collagen fibril diameters [104], and treatment of decorin
with decorin-null skin fibroblasts results in the formation of more uniform collagen fibrils
[105]. Fibromodulin-deficient tail tendons exhibit thinner collagen fibrils compared to wild-
type controls [106, 107]. A dynamic modulus in biglycan-null tendons is significantly increased
compared to wild-type tendons [108]. The elasticity of collagen fiber networks in cultured
decorin-siRNA-transfected mouse NIH3T3 fibroblasts is declined during the incubation
period, whereas it remains unchanged in untransfected cells. It is therefore likely that SLRPs
could regulate the physiological properties of ECM (e.g., mechanical strength).
3. Possible mechanisms of collagen network formation
As described in Section 2.1, it has been believed that collagen-network formation depends on
the fibronectin matrix in culture [12, 13]. Indeed, the prominent expression of fibronectin is
observed during adult tissue repair [11, 109]. Another line of evidence shows that TGF-β plays
a central role as a profibrogenic cytokine in the accumulation of ECMs, including fibronectin.
Therefore, it would be possible that TGF-β-induced ECM accumulation is dependent on
fibronectin. However, to date, fibronectin/TGF-β interdependence in the fibrogenic response
to tissue damage has not yet been addressed. Furthermore, it remains to be elucidated how
ECM remodeling by myofibroblasts results in changes in mechanical tension and supports the
activation of pathogenic signaling pathways during the development of chronic fibrotic
diseases. We hypothesized that the removal of fibronectin or TGF-β signaling in vivo could
prevent extensive ECM network formation following tissue damage. To define the functional
identity of fibronectin and TGF-β signaling in adult tissue remodeling, we recently established
two animal models lacking fibronectin (both isoforms) or TRII, respectively, in adult liver [14,
62]. Our new findings suggest fibronectin-/TGF-β-independent mechanisms are involved in
the development of liver fibrosis.
3.1. Fibronectin-dependent assembly
3.1.1. Fibronectin matrix assembly
Fibronectin matrix assembly consists of multistep process (Figure 1) [110–113]. Importantly,
fibronectin assembly is cell dependent; binding of fibronectin to cell surface and cellular
contractility are required. In the first step, fibronectin binds to cell surface, and integrin plays
an important role. Integrins α5β1 and αvβ3 are characterized as fibronectin receptors [114].
Lines of evidence show that α5β1 is a primary receptor in fibronectin matrix assembly, whereas
αvβ3 dominates the formation of focal contacts [115–117]. However, the binding of fibronectin
to the cell is not sufficient for fibronectin assembly. A critical step of this assembly is considered
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to be the cell-driven exposure of cryptic site for self-association in fibronectin. Although one
mechanism for exposing the cryptic site could be conformational changes induced by fibro‐
nectin binding to integrin, cellular contractility is necessary for fibronectin fibrillogenesis [88,
111, 118]. Indeed, loss of cellular contractility by RhoA inhibitor prevents fibronectin matrix
formation [119]. Furthermore, recent study demonstrates that β1 cytoplasmic domain modu‐
lates fibronectin assembly via recruitment of cytoplasmic adaptor protein talin, which links
integrin to the actin cytoskeleton [120, 121]. Thus, integrin-mediated association of fibronectin
with cytoskeleton is important for fibronectin assembly.
Figure 1. Proposed mechanism of fibronectin-dependent collagen assembly. (A) Type I collagen assembly with fibro‐
nectin. (B) Fibronectin assembly. ①Fibronectin binding to activated integrin; ②conformational changes of fibronectin
cryptic site by cellular contraction; ③exposure of fibronectin cryptic site, resulting in acquiring ability to associate with
other fibronectin molecules; and ④formation and extension of fibronectin fibril assembly. (C) Fibronectin structure.
See details in the text.
3.1.2. Collagen assembly with fibronectin matrix
Fibronectin contains collagen-binding domain [122] and directly binds to collagens. In vitro
studies have shown an extensive codistribution of fibronectin and Col I/III (Figure 1) [12,
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123]. A very recent study using fibroblasts demonstrates that type I collagen fibrils preferen‐
tially colocalize with more-relaxed fibronectin fibrils in the ECM in vitro [124]. Fibronectin-null
embryonic fibroblastic cells cannot organize collagen fibril networks in vitro, but they can form
collagen networks when fibronectin is exogenously added [123]. Interestingly, collagen-
binding integrins α2β1 and α11β1 are not required for collagen polymerization in fibronectin-
null embryonic fibroblastic cells when cultured with exogenous fibronectin [12]. Furthermore,
integrin β1-null line GD25 cells, which express fibronectin and its receptor αvβ3, contract
collagen gel more forcefully than integrin α2- and β1-transfected GD25 cells that contract
collagen gel via α2β1 but not αvβ3 [125]. Other studies show that fibronectin polymerization
stimulates collagen gel contraction [126] and that the disruption of fibronectin–collagen
association inhibits this contraction [13]. These findings demonstrate that fibronectin matrix
is required for collagen assembly and enhances ECM contraction of cells.
3.1.3. Initial incorporation of latent TGF-β complex
Growing evidence suggests a mechanism by which fibronectin plays a role in the initial
incorporation of latent TGF-β complex into ECM [18, 33]. LTBP-1 associates with not only
fibrillin-1 but also fibronectin [33, 36]. Fibronectin-null fibroblasts fail to incorporate LTBP into
ECM [33], and minimally activate latent TGF-β [127]. Furthermore, cells lacking fibronectin
receptor integrin α5β1 show defective activity of latent TGF-β by αvβ6 [127]. These findings
suggest that fibronectin regulates latent TGF-β activation via deposition of latent TGF-β into
the matrix.
3.2. Fibronectin-independent collagen assembly
As described above, based on in vitro findings, it has been postulated that collagen network
organization and assembly depends on the fibronectin matrix in culture [12, 13]. However, the
contribution of fibronectin to these processes remains to be defined in vivo. We therefore
investigated whether fibronectin is a suitable molecular target for ameliorating the fibrogenic
response to liver injury. Since mice with complete inactivation of fibronectin gene die at an
early embryonic stage [10], we generated conditional fibronectin-floxed and liver-specific
adult fibronectin-null mice (lacking both plasma and cellular isoforms of fibronectin) using
Cre-loxP technology [11, 14], investigated their phenotypes, and have demonstrated fibronec‐
tin-independent mechanisms for collagen network formation following liver injury.
3.2.1. TGF-β and Col V-mediated collagen assembly in fibronectin-null liver
The adult mouse model lacking fibronectin shows no abnormalities in anatomical and
histological analyses of the liver and hepatic biochemical markers under standard laboratory
conditions. Unexpectedly, the lack of fibronectin did not interfere with the reconstruction of
collagen fibril organization in response to both acute liver and chronic liver injuries up to 8
weeks induced by CCl4 [14]. Fibronectin-null livers show significant increased HSC activation
with elevated Smad signaling following injury. To determine whether TGF-β is involved in
Col III/I collagen network formation in the absence of fibronectin, we further assessed which
factors that regulate activated HSC phenotypes were involved in collagen fibrillogenesis. We
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have identified TGF-β1-induced Col V as a novel and essential element for Col I/III fibrogenesis
in hepatic stellate cells (Figure 2). Thus, our study provides compelling evidence that collagen
fibrillogenesis in response to adult tissue/organ damage is mediated by both fibronectin and
type V collagen.
Figure 2. Proposed mechanism of fibronectin-independent collagen assembly mediated by tissue growth factor beta
(TGF-β) signaling and type V collagen (Col V). (A) Type I collagen assembly with Col V. (B) Pro-α1(V) collagen struc‐
ture. PARP, proline- and arginine-rich domain; VAR, variable domain. (C) Local TGF-β activation. See details in the
text.
Interestingly, type V collagen–mediated Col III/I fibril assembly following liver injury seems
to be specific for adult HSCs because TGF-β1 supports neither Col V nor Col III/I fibril assembly
in fibronectin-null embryonic fibroblasts in vitro [14]. Furthermore, fibronectin-null livers
show substantial depositions of LTBP-1, -3, and -4 with fibrillar structures in the ECM
following both acute and chronic liver injuries [14, 65], whereas fibronectin-null embryonic
fibroblasts fail to incorporate LTBP-1 into ECM in vitro [33]. Therefore, further studies for
mechanisms underlying Col V-mediated collagen network formation remain to be elucidated,
i.e., the phenotypic differences among myofibroblasts, and the contribution to adult tissue/
organ remodeling following injury.
3.2.2. Elevated collagen matrix stiffness in advanced stage of liver fibrosis/cirrhosis in fibronectin-null
liver
We showed that collagen network organization can be formed even without fibronectin in
response to liver injury [14]. However, it remains unknown whether the initial deposition of
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fibronectin could contribute to the turning point from normal healing to chronic fibrotic
disorders. Furthermore, it remains to be elucidated how ECM remodeling by myofibroblasts
affects mechanical tension and supports the activation of pathogenic signaling during the
development of chronic fibrotic diseases. We therefore have further investigated whether
fibronectin could be a suitable target for ameliorating fibrosis during advanced stages of
chronic liver injury [65]. Fibronectin-null livers have exhibited constitutively elevated local
TGF-β activity, induced more myofibroblast phenotypes, and accumulated highly disorgan‐
ized/diffused collagenous ECM networks during chronic liver fibrogenesis induced by CCl4.
The deposition and network formation of Col V are also significantly increased. Consequently,
fibronectin-null livers have led to more extensive liver cirrhosis, which is accompanied by
significant increased liver matrix stiffness and deteriorated hepatic functions. Mechanistically,
fibronectin-null livers have shown elevated LOX expressions, and a significant amount of
active LOX is released in fibronectin-null hepatic stellate cells in response to TGF-β1. Further‐
more, treatment of fibronectin in fibronectin-null stellate cells recovers collagen fibril stiffness
to wild-type levels [65].
We propose that there are the functional links between fibronectin-mediated control of TGF-
β bioavailability and collagen fibril stiffness regulated by LOX. All these novel findings
strongly suggest that locally activated TGF-β signaling and Col V are essential elements for
collagen fibrogenesis without fibronectin in adult tissue remodeling. Although the contribu‐
tion of Col V-nucleated Col I fibrogenesis in adult tissues is largely undetermined, our finding
raises the hypothesis that the accumulation of Col V-mediated ECMs during persistent chronic
damage could influence a formation of disorganized ECM architecture.
3.3. TGF-β-independent collagen assembly
3.3.1. CTGF-mediated collagen assembly
TGF-β signaling is the dominant pathway of ECM productions in HSCs [58]. To address
whether the elimination of this signaling is sufficient to prevent liver fibrosis, we have
generated adult liver-specific TRII-null mice (TGFβIIR[flox/flox]/Mx-Cre+) [62]. Actually, this
mutant liver exhibits a significant decrease of ECM deposition and α-SMA expression in
CCl4-induced chronic liver injury. However, elimination of TRII does not completely prevent
the collagen accumulation in chronic liver injury, and TRII-null livers still remain ~46.4%
fibrosis compared to wild type. Furthermore, we have found that matricellular protein CTGF/
CCN2 expression is significantly upregulated (1.94-fold compared to wild type) in mutant
livers following chronic liver injury. Therefore, these findings clearly indicate that TGF-β-
independent mechanisms play an alternative role in developing liver fibrosis. Since CTGF/
CCN2 synergizes with the action of TGF-β, CTGF/CCN2 is considered to act as a TGF-β
downstream modulator [128]. Accompanied by the elevated TGF-β activity, CTGF/CCN2
expression is upregulated in several fibrotic tissues, including kidney, lung, heart, liver,
pancreas, bowel, and skin [128, 129]. A recent study has demonstrated that overexpression of
CTGF/CCN2 in fibroblasts alone is sufficient to cause spontaneous multiorgan fibrosis in
vivo and that this signal pathway does not involve canonical TGF-β-Smad signaling in vitro.
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However, the liver does not show significant fibrosis [130]. We have found that TRII-null livers
in chronic injury show elevated expression of CTGF/CCN2 in spite of a lack of TGF-β signaling,
indicating CTGF/CCN2 as a potent mediator in liver fibrosis [62]. We propose two hits,
induction of CTGF/CCN2 and adult tissue/organ injury, for the progression of liver fibrosis.
In fibrotic livers, CTGF/CCN2 is known to be synthesized in a diversity of cells such as
hepatocytes, myofibroblasts (activated HSCs), endothelial cells, proliferating bile duct
epithelial cells, and inflammatory cells [128]. Thus, it remains to be elucidated to identify
cellular contribution and mechanisms underlying CTGF/CCN2 production in the progression
of tissue/organ fibrosis.
4. Perspective
Novel findings obtained imply that fibronectin regulates the balance between active and
inactive (latent) TGF-β, which in turn modulates ECM production and remodeling following
injury, and consequently retains adult tissue/organ functions. This regulatory mechanism by
fibronectin could be translated for a potential therapeutic target in a broader variety of chronic
fibrotic diseases. It is obvious that fibronectin matrix networks play crucial roles in many
important biological events and in adult homeostasis. Therefore, the regulation of TGF-β
bioavailability by fibronectin with retaining fibronectin matrix networks would be an essential
element for long-term antifibrotic strategies in chronic fibrotic diseases to preserve tissue/
organ function and homeostasis.
Considering the adult tissue/organ remodeling following injury, important unresolved
questions are (1) what is the trigger for fibrosis resolution (regression); and (2) how fibrosis
resolution proceeds. Quiescent HSCs are adipocyte-like (vitamin A stock) cells expressing
marker genes such as PPARγ, SREBP-1c, and leptin, whereas activated HSCs are proliferative
myofibroblasts expressing myogenic marker α-SMA, c-myb, and MEF-2 [131]. CCl4-induced
experimental liver injury models have suggested that elimination of activated HSCs by
apoptosis [132] or senescence [133] is a key step in the onset of fibrosis regression [134].
Growing evidence demonstrates that activated HSCs are reverted to quiescent-like state both
in vitro [135, 136] and in vivo [137, 138], and a very recent in vitro study using human primary
HSCs reveals EGF, fibroblast growth factor 2, fatty acids, and retinol as potential factors in
activated HSCs to reverse quiescent-like phenotypes [139]. Interestingly, reverted HSCs show
more rapid reactivation into myofibroblasts in response to TGF-β than quiescent HSCs [137].
It is therefore likely that reverted HSCs may not fully revert to a quiescent state [134]. A recent
elegant study demonstrates that a history of liver injury is transmitted to offspring via
epigenetic modification of PPARγ and TGF-β genes in rats, and consequently, healing
response to hepatic injury is suppressed in offspring of CCl4-injured group compared to injury-
inexperienced group [140]. Nevertheless, the clarification of molecular mechanisms underly‐
ing excessive accumulation of collagenous ECM during the development of chronic fibrotic
diseases could translate basic antifibrotic research into improved clinical therapeutic ap‐
proaches, which will have a significant benefit in public health impact. Thus, an establishment
of novel models/systems, e.g., in which we enable to analyze global alterations of signaling
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cascades/metabolisms or epigenetics, would be crucial for challenging these complicated
mechanisms in chronic fibrotic diseases.
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